Favorable Safety Profile Seen With Sabizabulin in mCRPC
Mark Markowski, MD, PhD, discusses the results of a phase 1b/2 study examining treatment with sabizabulin in patients with metastatic castration-resistant prostate cancer.
Sabizabulin for the Treatment of Men With mCRPC
Mark Markowski, MD, PhD, discusses the design of a phase 1B/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who have had treatment and progression on an androgen receptor–targeting agent.